Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899127 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL9694450 | 0.82 | CA12 (0.41) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL1682652 | 0.82 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL2045307 | 0.77 | KDM4E (0.32) | — | |
| SCHEMBL31463755 | 0.75 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7912591 | 0.75 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL30184336 | 0.75 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL21339599 | 0.75 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL12647857 | 0.75 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL13497230 | 0.74 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | CHRM2 85/4885CHRM1 58/4885CHRM4 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.